283 related articles for article (PubMed ID: 32651218)
1. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.
Orlov M; Wander PL; Morrell ED; Mikacenic C; Wurfel MM
J Immunol; 2020 Aug; 205(4):892-898. PubMed ID: 32651218
[TBL] [Abstract][Full Text] [Related]
2. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
3. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
Weiskopf D; Schmitz KS; Raadsen MP; Grifoni A; Okba NMA; Endeman H; van den Akker JPC; Molenkamp R; Koopmans MPG; van Gorp ECM; Haagmans BL; de Swart RL; Sette A; de Vries RD
Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32591408
[TBL] [Abstract][Full Text] [Related]
4. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Wan MT; Shin DB; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2020 Aug; 83(2):677-679. PubMed ID: 32416207
[No Abstract] [Full Text] [Related]
5. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
6. Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy.
Cafarotti S
J Thorac Oncol; 2020 Jul; 15(7):e101-e103. PubMed ID: 32353597
[TBL] [Abstract][Full Text] [Related]
7. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Yao Z; Zheng Z; Wu K; Junhua Z
Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
9. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
11. Complement as a target in COVID-19?
Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
[TBL] [Abstract][Full Text] [Related]
12. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
13. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.
El-Missiry MA; El-Missiry ZMA; Othman AI
Eur J Pharmacol; 2020 Sep; 882():173329. PubMed ID: 32615182
[TBL] [Abstract][Full Text] [Related]
14. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
Castelli V; Cimini A; Ferri C
Front Immunol; 2020; 11():2132. PubMed ID: 32983172
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
Front Immunol; 2020; 11():2056. PubMed ID: 32973814
[TBL] [Abstract][Full Text] [Related]
16. Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.
Facheris P; Valenti M; Pavia G; Gargiulo L; Narcisi A; Costanzo A; Borroni RG
Int J Dermatol; 2020 Aug; 59(8):e267-e268. PubMed ID: 32557532
[No Abstract] [Full Text] [Related]
17. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
Carnero Contentti E; Correa J
Mult Scler Relat Disord; 2020 Jun; 41():102097. PubMed ID: 32278860
[No Abstract] [Full Text] [Related]
19. Viral and host factors related to the clinical outcome of COVID-19.
Zhang X; Tan Y; Ling Y; Lu G; Liu F; Yi Z; Jia X; Wu M; Shi B; Xu S; Chen J; Wang W; Chen B; Jiang L; Yu S; Lu J; Wang J; Xu M; Yuan Z; Zhang Q; Zhang X; Zhao G; Wang S; Chen S; Lu H
Nature; 2020 Jul; 583(7816):437-440. PubMed ID: 32434211
[TBL] [Abstract][Full Text] [Related]
20. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
